GLUTAMINASE INHIBITORS

• US 20190309017A1
• Filed: 10/05/2018
• Published: 10/10/2019
• Est. Priority Date: 04/09/2018
• Status: Abandoned Application

• Current Assignee: Glutaminax Incorporated
• Original Assignee: Glutaminax Incorporated
• Inventors: Swiss, Gerald F.
• Application Number:
  US16/153,532
• Publication Number:
  US 20190309017A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 5/0215 containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
• CPC Class Codes: C07K 5/06026 the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Abstract

Disclosed are newly identified chemotherapeutic agents. These inhibitors are particularly useful in the treatment of cancers such as leukemic cells and pancreatic cancers.

Claims

1. A compound of the formula:

2. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient.

3. A method for killing multiple myeloma cells which method comprises contacting said cells with an effective amount of a compound of claim 1.

4. A method for killing multiple myeloma cells which method comprises contacting said cells with an effective amount of a pharmaceutical composition of claim 2.

9. A method for killing pancreatic cancer cells which method comprises contacting said cells with an effective amount of a compound of claim 1.

10. A method for killing pancreatic cancer cells which method comprises contacting said cells with an effective amount of a pharmaceutical composition of claim 2.

5. A compound of the formula:

6. A pharmaceutical composition comprising an effective amount of a compound of claim 5 and a pharmaceutically acceptable excipient.

7. A method for killing multiple myeloma cells which method comprises contacting said cells with an effective amount of a compound of claim 5.

8. A method for killing multiple myeloma cells which method comprises contacting said cells with an effective amount of a pharmaceutical composition of claim 6.

11. A method for killing pancreatic cancer cells which method comprises contacting said cells with an effective amount of a compound of claim 5.

12. A method for killing pancreatic cancer cells which method comprises contacting said cells with an effective amount of a pharmaceutical composition of claim 6.